ClinicalTrials.gg
Not yet recruitingNCT07764107Updated Nov 16, 2026

Photobiomodulation for Reducing Sedative-Hypnotic Use:Clinical Trial of a Light-Therapy Device

An interventional study of 660 nm Visible Red Light and 850 nm Near-Infrared Light in Insomnia, sponsored by National Health Research Institutes, Taiwan. Not yet recruiting. Open to participants aged 20 Years to 100 Years. Per ClinicalTrials.gov, last updated 2026-11-16.

Sponsored by National Health Research Institutes, Taiwan · Not applicable, Interventional, and Treatment

Updated Nov 16, 2026Start date movedEnrollment updated+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
90
Allocation
Randomized
Ages
20 Years to 100 Years
Sex
All
01

Study summary

Background: Insomnia is a prevalent and growing public health issue, with one in three adults affected globally and one in five Taiwanese adults reporting significant sleep disturbances. Long-term use of sedative-hypnotic medications remains common in Taiwan despite clinical guidelines recommending short-term use only, contributing to adverse outcomes such as impaired sleep architecture, cognitive deficits, and elevated dementia risk. Non-pharmacological interventions-particularly light-based therapies-offer promising alternatives but existing bright-light therapy is limited by melatonin suppression and the need for precise daytime timing. Recent advances in photobiomodulation (PBM) suggest that red and near-infrared light, which do not suppress melatonin, may enhance sleep quality and support glymphatic clearance when applied during sleep. Preliminary findings from our prior NSTC-funded industry-academia project demonstrated that 850-nm PBM applied during sleep improved subjective sleep quality and sleep duration among older adults with insomnia who were not using hypnotics. Building on these results, the present study aims to evaluate whether sleep-period PBM can improve sleep quality, enhance daytime alertness and cognitive function, and reduce sedative-hypnotic medication use among adults with chronic insomnia who regularly use these medications.

Methods: This project will employ a four-week single-blind, randomized controlled trial with three parallel arms: (1) a 660-nm visible red-light group, in which participants will wear the light device for one hour before bedtime each night; (2) an 850 ± 10-nm near-infrared light group, in which participants will wear the light device for one hour before bedtime each night, and (3) a sham control group using an inactive 630-nm red-light device. We will develop a wearable prototype that has undergone engineering validation. A total of 90 adults with chronic insomnia who use sedative-hypnotic medications on at least four days per week will be recruited and randomly assigned in a 1:1:1 ratio to the three study groups. Participants will be instructed to wear the assigned device continuously at the cymba choncae. Outcome assessments will be conducted at baseline and week 4, and will be followed at the 12th week. Primary outcomes will include subjective sleep quality measured by the Pittsburgh Sleep Quality Index (PSQI), frequency of hypnotic medication use, and objective sleep parameters assessed by actigraphy. Secondary outcomes will include daytime sleepiness assessed by the Karolinska Sleepiness Scale (KSS), mood symptoms assessed by the Beck Depression Inventory (BDI) and Beck Anxiety Inventory (BAI), and performance on the Psychomotor Vigilance Task (PVT).

Expected contributions: This study is expected to generate clinical evidence in Taiwan evaluating nighttime PBM for insomnia in hypnotic-using populations, address the unmet need for portable, home-based, non-pharmacological sleep interventions, and support future commercialization of a sleep-compatible light therapy device. Results will inform device optimization, regulatory approval strategies, and market expansion efforts in the growing global sleep-health industry.

02

Conditions studied

  • Insomnia

Keywords

  • Aging; Clinical Trial; Light therapy; Near-infrared; Photobiomodulation; Sleep.
03

In context

Sleep Initiation and Maintenance Disorders

2,729 studies on the registry are indexed under Sleep Initiation and Maintenance Disorders; 731 are open to participants now.

This study's planned enrollment of 90 is above the median of 68 across 2,356 interventional studies indexed under Sleep Initiation and Maintenance Disorders.

Browse Sleep Initiation and Maintenance Disorders studies →

Lead sponsor

National Health Research Institutes, Taiwan is the lead sponsor of 129 studies on the registry; 31 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

The criteria were revised on the registry on Nov 16, 2026. See what changed

Ages eligible
20 Years to 100 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 20 years or older.
  • A Pittsburgh Sleep Quality Index (PSQI) score of 8 or above.
  • Currently taking sedative-hypnotic medications at least 4 days per week.

Exclusion criteria

Exclusion Criteria:

  • Having a movement disorder, including Parkinson's disease or moderate to severe dementia, resulting in an inability to ambulate independently.
  • Having major psychiatric comorbidities, such as bipolar disorder or schizophrenia, or a Beck Depression Inventory-II (BDI-II) score greater than 13.
  • Having a history of sleep disorders, including sleep apnea or periodic limb movement disorder.
  • Currently undergoing clinical adjustment of sleep medications.
  • Having skin damage at the irradiation site or an active skin disease under treatment.
  • Working night shifts or having other reasons that prevent a regular nighttime sleep schedule.
  • Pregnancy.
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
90 participants (estimated)

Study arms

  • Experimental
    660 nm Visible Red Light

    Participants will receive 660 nm visible red light before bedtime for 1 hour per night for 4 consecutive weeks. The light is delivered to the bilateral cymba concha using a wearable light device, with a pulse frequency of 40 Hz and an irradiance of 2.0 ± 0.2 mW/cm².

    Device: 660 nm Visible Red Light

  • Experimental
    850 nm Near-Infrared Light

    Participants will receive 850 ± 10 nm near-infrared light before bedtime for 1 hour per night for 4 consecutive weeks. The light is delivered to the bilateral cymba concha using a wearable light device, with a pulse frequency of 40 Hz and an irradiance of 12.5 ± 1.25 mW/cm².

    Device: 850 nm Near-Infrared Light

  • Sham comparator
    630 nm Sham Control

    Participants will receive 630 nm visible red light as a sham comparator before bedtime for 1 hour per night for 4 consecutive weeks.

    Device: 630 nm Sham Control

Interventions

  • Device660 nm Visible Red Light

    Participants will receive 660 nm visible red light before bedtime for 1 hour per night for 4 consecutive weeks. The light will be delivered to the bilateral cymba concha using a wearable light device, with a pulse frequency of 40 Hz and an irradiance of 2.0 ± 0.2 mW/cm².

  • Device850 nm Near-Infrared Light

    Participants will receive 850 ± 10 nm near-infrared light before bedtime for 1 hour per night for 4 consecutive weeks. The light will be delivered to the bilateral cymba concha using a wearable light device, with a pulse frequency of 40 Hz and an irradiance of 12.5 ± 1.25 mW/cm².

  • Device630 nm Sham Control

    Participants will receive 630 nm visible red light as a sham comparator before bedtime for 1 hour per night for 4 consecutive weeks. The light will be delivered using a wearable light device.

06

What researchers measure

Primary outcomes

  1. Sleep quality measured by the Pittsburgh Sleep Quality Index (PSQI)

    The Pittsburgh Sleep Quality Index (PSQI) is used to assess sleep quality. The PSQI consists of seven components, each scored from 0 to 3, with a total score ranging from 0 to 21. Higher scores indicate poorer sleep quality.

    Time frame: baseline, week 4, and week 12

  2. Sedative-hypnotic medication use frequency

    The frequency of sedative-hypnotic medication use will be assessed on a weekly basis to evaluate changes in medication use following the intervention.

    Time frame: baseline, week 5, and week 12

  3. Actigraphy-derived sleep parameters

    Sleep parameters will be assessed using a wrist-worn actigraphy device. The measured parameters include average sleep duration, sleep onset latency, wake after sleep onset, and sleep efficiency.

    Time frame: baseline and week 5

Secondary outcomes

  1. Daytime sleepiness

    Daytime sleepiness will be assessed using the Karolinska Sleepiness Scale (KSS).

    Time frame: baseline, week 5, and week 12

  2. Psychomotor vigilance performance

    Psychomotor vigilance performance will be assessed using a 3-minute psychomotor vigilance test (PVT) administered via smartphone. Outcomes include the number of lapses, mean reaction time, error number, reciprocal mean reaction time, and the fastest and slowest 10% reaction times.

    Time frame: baseline and week 5

  3. Heart rate variability

    Heart rate variability (HRV) will be assessed to evaluate autonomic nervous system activity. Frequency-domain measures will include total power (TP), very low frequency (VLF), low frequency (LF), high frequency (HF), LF/HF ratio, LF%, and HF%.

    Time frame: baseline and week 5

  4. Sleep chronotype and sleep timing

    Sleep chronotype and sleep timing will be assessed using the Munich Chronotype Questionnaire (MCTQ), including sleep timing preference, bedtime, and wake-up time.

    Time frame: baseline, week 5, and week 12

  5. Depressive symptoms

    Depressive symptoms will be assessed using the Beck Depression Inventory-II (BDI-II).

    Time frame: baseline, week 5, and week 12

  6. Anxiety symptoms

    Anxiety symptoms will be assessed using the Beck Anxiety Inventory (BAI).

    Time frame: baseline, week 5, and week 12

  7. Sedative-hypnotic dependence severity

    Severity of sedative-hypnotic dependence will be assessed using the Severity of Dependence Scale (SDS).

    Time frame: baseline, week 5, and week 12

07

Study locations

No study locations are listed for this record.

08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Dec 2026; primary completion for May 2027, 4 months later.

Of 1,212 non-industry interventional studies with no phase under Sleep Initiation and Maintenance Disorders, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 35. This study's planned 4 months is below that.

Counting every sponsor, half of 1,290 studies reached it within 15 months; a quarter within 6 and three quarters within 34.

Start moved once since we started tracking on Sep 25, 2026: Aug 2026 → Dec 2026, on Nov 16, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Aug 9, 2026
First posted
Aug 13, 2026
StartEst.
Dec 20, 2026was Aug 2026
Primary completionEst.
May 5, 2027
CompletionEst.
May 5, 2027
Last update
Nov 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Start date
Aug 1, 2026→Dec 20, 2026
Nov 16, 2026
Enrollment
60→90
Nov 16, 2026
Eligibility
1 inclusion criterion added; 4 exclusion criteria edited, 2 added, 2 removed
What changed in the criteria
Inclusion criteria
  • AddedAge 20 years or older.
Exclusion criteria
  • EditedHaving a movement disorder, including Parkinson's disease or moderate to severe dementia, resulting in an inability to ambulate independently.
  • EditedAHaving a history of sleep disorders, such as obstructiveincluding sleep apnea or periodic limb movement disorder.
  • EditedCurrently undergoing clinical adjustment of sleep medications in clinical care.
  • EditedSkinHaving skin damage or active dermatologic conditions at the irradiation site or an active skin disease under treatment.
  • RemovedNight-shift workers or individuals unable to maintain regular nighttime sleep for other reasons.
  • RemovedPregnant women.
  • AddedWorking night shifts or having other reasons that prevent a regular nighttime sleep schedule.
  • AddedPregnancy.
Nov 16, 2026
Interventions
Added Device: 660 nm Visible Red Light·Device: 850 nm Near-Infrared Light·Device: 630 nm Sham Control; removed Device: PBM intervention·Device: Inactive sham control. Arms added: 660 nm Visible Red Light·850 nm Near-Infrared Light·630 nm Sham Control; arms removed: PBM intervention·Inactive sham control
Nov 16, 2026
Primary outcomes
1 edited, 2 added, 2 removed
What changed in the outcomes
  • EditedHypnoticSedative-hypnotic medication use frequencyTime frame: baseline, week 4, and week 8 → baseline, week 5, and week 12
  • AddedSleep quality measured by the Pittsburgh Sleep Quality Index (PSQI)Time frame: baseline, week 4, and week 12
  • AddedActigraphy-derived sleep parametersTime frame: baseline and week 5
  • RemovedSleep qualityTime frame: baseline, week 4, and week 8
  • RemovedActigraphyTime frame: baseline, week 4, and week 8
Nov 16, 2026
Secondary outcomes
1 time frame changed, 6 added, 1 description edited
What changed in the outcomes
  • AddedPsychomotor vigilance performanceTime frame: baseline and week 5
  • AddedHeart rate variabilityTime frame: baseline and week 5
  • AddedSleep chronotype and sleep timingTime frame: baseline, week 5, and week 12
  • AddedDepressive symptomsTime frame: baseline, week 5, and week 12
  • AddedAnxiety symptomsTime frame: baseline, week 5, and week 12
  • AddedSedative-hypnotic dependence severityTime frame: baseline, week 5, and week 12
  • Time frameDaytime sleepinessbaseline, week 4, and week 8. → baseline, week 5, and week 12
  • DescriptionDaytime sleepiness: how it is measured was reworded
Nov 16, 2026
Show all 1 update
  1. Nov 16, 2026
    Start date Aug 1, 2026→Dec 20, 2026
    Enrollment 60→90
    Eligibility 1 inclusion criterion added; 4 exclusion criteria edited, 2 added, 2 removed
    What changed in the criteria
    Inclusion criteria
    • AddedAge 20 years or older.
    Exclusion criteria
    • EditedHaving a movement disorder, including Parkinson's disease or moderate to severe dementia, resulting in an inability to ambulate independently.
    • EditedAHaving a history of sleep disorders, such as obstructiveincluding sleep apnea or periodic limb movement disorder.
    • EditedCurrently undergoing clinical adjustment of sleep medications in clinical care.
    • EditedSkinHaving skin damage or active dermatologic conditions at the irradiation site or an active skin disease under treatment.
    • RemovedNight-shift workers or individuals unable to maintain regular nighttime sleep for other reasons.
    • RemovedPregnant women.
    • AddedWorking night shifts or having other reasons that prevent a regular nighttime sleep schedule.
    • AddedPregnancy.
    Primary outcomes 1 edited, 2 added, 2 removed
    What changed in the outcomes
    • EditedHypnoticSedative-hypnotic medication use frequencyTime frame: baseline, week 4, and week 8 → baseline, week 5, and week 12
    • AddedSleep quality measured by the Pittsburgh Sleep Quality Index (PSQI)Time frame: baseline, week 4, and week 12
    • AddedActigraphy-derived sleep parametersTime frame: baseline and week 5
    • RemovedSleep qualityTime frame: baseline, week 4, and week 8
    • RemovedActigraphyTime frame: baseline, week 4, and week 8
    Secondary outcomes 1 time frame changed, 6 added, 1 description edited
    What changed in the outcomes
    • AddedPsychomotor vigilance performanceTime frame: baseline and week 5
    • AddedHeart rate variabilityTime frame: baseline and week 5
    • AddedSleep chronotype and sleep timingTime frame: baseline, week 5, and week 12
    • AddedDepressive symptomsTime frame: baseline, week 5, and week 12
    • AddedAnxiety symptomsTime frame: baseline, week 5, and week 12
    • AddedSedative-hypnotic dependence severityTime frame: baseline, week 5, and week 12
    • Time frameDaytime sleepinessbaseline, week 4, and week 8. → baseline, week 5, and week 12
    • DescriptionDaytime sleepiness: how it is measured was reworded
    Interventions Added Device: 660 nm Visible Red Light·Device: 850 nm Near-Infrared Light·Device: 630 nm Sham Control; removed Device: PBM intervention·Device: Inactive sham control. Arms added: 660 nm Visible Red Light·850 nm Near-Infrared Light·630 nm Sham Control; arms removed: PBM intervention·Inactive sham control
    + 3 other changes: description, conditions and design details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07764107
Responsible party
Sponsor
First posted
Aug 13, 2026
Start date
Dec 20, 2026 (estimated)
Primary completion
May 5, 2027 (estimated)
Completion
May 5, 2027 (estimated)
Last update
Nov 16, 2026

Study contacts

Wan-Ju Cheng Ph.D
Contact
s871065@gmail.com
+886975682566

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in May 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion